Key Takeaways Exact Sciences unveiled Cancerguard, a new multi-cancer early detection blood test in the United States.EXAS' Cancerguard showed 64% sensitivity across cancers and 97.4% specificity to limit false positives.The company is enrolling 25,000 in the Falcon study to support coverage and future FDA submissions.Exact Sciences Corporation (EXAS) has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States. ...

While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more. TransMedics Group developed a revolutionary way to store organs before transplants. The company's Organ Care System (OCS) mimics the physiology of the human body, resulting in a higher u ...